Delcath Systems

Delcath is a commercial-stage interventional oncology company dedicated to revolutionizing the treatment of patients with cancer in their liver. Headquartered in the United States, Delcath focuses on developing targeted, safe, and effective minimally-invasive treatments for primary and metastatic liver cancers, including the FDA-approved Hepzato Kit™ for adult patients with metastatic uveal melanoma.